"Insulin Lispro" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Insulin that has been modified so that the B-chain contains a LYSINE at position 28 instead of a PROLINE and a PROLINE at position 29 instead of a LYSINE. It is used to manage BLOOD GLUCOSE levels in patients with TYPE 2 DIABETES.
| Descriptor ID |
D061268
|
| MeSH Number(s) |
D06.472.699.587.200.400.500 D12.644.548.586.200.400.500
|
| Concept/Terms |
Insulin Lispro- Insulin Lispro
- Lispro, Insulin
- 28(B)-Lys-29(B)-Pro-Insulin
- 28(B)-Lysine-29(B)-Prolineinsulin
- Insulin, Lysyl(28B)-Prolyl(28B)-
- Lispro
- LYSPRO
- Insulin, Lys(28B)-Pro(29B)-
|
Below are MeSH descriptors whose meaning is more general than "Insulin Lispro".
Below are MeSH descriptors whose meaning is more specific than "Insulin Lispro".
This graph shows the total number of publications written about "Insulin Lispro" by people in this website by year, and whether "Insulin Lispro" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Insulin Lispro" by people in Profiles.
-
Kastner JR, Bailey TS, Strange P, Shi L, Oberg KA, Strasma PJ, Joseph JI, Muchmore DB. Progressive Acceleration of Insulin Exposure Over 7 Days of Infusion Set Wear. Diabetes Technol Ther. 2023 02; 25(2):143-147.
-
Legg KM, Labay LM, Aiken SS, Logan BK. Validation of a Fully Automated Immunoaffinity Workflow for the Detection and Quantification of Insulin Analogs by LC-MS-MS in Postmortem Vitreous Humor. J Anal Toxicol. 2019 Aug 23; 43(7):505-511.
-
Simon B, Treat V, Marco C, Rosenberg D, Joseph J, Hipszer B, Li Y, Chervoneva I, Padron-Massara L, Jabbour S. A comparison of glycaemic variability in CSII vs. MDI treated type 1 diabetic patients using CGMS. Int J Clin Pract. 2008 Dec; 62(12):1858-63.